11:43:46 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-16 Kvartalsrapport 2024-Q1
2024-05-13 Ordinarie utdelning DEAR 0.00 SEK
2024-05-08 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2024-01-31 Extra Bolagsstämma 2024
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-04 Kvartalsrapport 2023-Q1
2023-04-13 Ordinarie utdelning DEAR 0.00 SEK
2023-04-12 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Kvartalsrapport 2022-Q1
2022-04-08 Ordinarie utdelning DEAR 0.00 SEK
2022-04-07 Årsstämma 2022

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Duearity är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling och produktion av tekniska lösningar för behandling och lindring av tinnitus. Produktportföljen inkluderar exempelvis bolagets egenutvecklade produkter Tinearity och Duearity. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs inom Sverige.
2021-11-02 08:41:00

Duearity has conducted a proof of concept as the first stage of its development program for the company’s AI system. A prototype system has been built to prove the viability of the company’s concept. The AI system is designed to help people suffering from tinnitus manage their symptoms, thereby relieving their tinnitus. It’s expected to be ready to launch in 2024 and has the potential to generate considerable revenues for the company. There is no system available at this time within the field of tinnitus that is similar to Duearity’s concept, making it unique in the field. A patent has already been applied for.

Duearity has successfully conducted a proof of concept study to support development of a unique AI system for people suffering from tinnitus. The system can be used both by individuals to manage their tinnitus symptoms and in Tinnitus Retraining Therapy (TRT), the most widespread treatment method. Duearity has previously applied for a patent to protect the AI system.

There has been considerable market interest, most notably from audiologists and other key players. Duearity’s AI solution will be expected to generate considerable revenues for the company as of 2024.

It consists of five functions. The first involves measuring a number of vital signs using a device located at a particular point on the body.

The second is an app that regularly monitors vital signs, such as stress levels and the individual’s perception of their tinnitus symptoms. The app visualises the link between lifestyle factors, body functions and the person’s tinnitus symptoms.

The third function is a cloud solution that uses algorithms to analyse the data gathered. The objective is to analyse and draw conclusions about the person’s symptoms and identify factors that improve and worsen symptoms. By linking vital signs and symptoms, the AI system will be able to predict when an individual’s symptoms are worsening and provide a warning, thereby giving the individual the opportunity to manage their tinnitus.

The fourth function is the fully-developed Tinearity sound element feature, which is constantly synced to the app and reacts to changes in tinnitus symptoms. The objective is to provide rapid relief of symptoms.

The fifth function is data analysis, meant to give insight and knowledge. We hope that in time, this data can be used by scientists to gain a deeper understanding of tinnitus and thus be able to find better and more effective treatment methods.

A major advantage of the AI system is that it will be usable within TRT, the most widespread and accepted treatment in use. TRT is a combination of Cognitive Behavioural Therapy (CBT) with a psychologist or therapist and listening to white noise. Tinnitus symptoms change continuously, from day-to-day and sometimes even from hour-to-hour. A big problem today is that both the patient and the psychologist find it hard to define when exactly a symptom worsened and the underlying factors that made it worse. The AI system is designed to improve TRT treatment by making it easier to identify situations that cause patients to suffer and that trigger worsening symptoms. This will improve the chances of successful treatment.